NEW YORK (GenomeWeb) – Illumina has submitted a companion diagnostic test it developed in conjunction with pharmaceutical company Amgen to the US Food and Drug Administration for pre-market approval, the company said this week.
The submission is just one example of the company's continued move into the oncology market, Illumina CEO and President Francis deSouza said during a conference call discussing the firm's third quarter 2016 results.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
